Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fondaparinux sodium.

J C Reverter1

  • 1Hemotherapy and Hemostasis Department, Hospital Clinic, Barcelona, Spain. REVERTER@clinic.ub.es

Drugs of Today (Barcelona, Spain : 1998)
|January 18, 2003
PubMed
Summary

Fondaparinux, a synthetic pentasaccharide, effectively prevents and treats thromboembolic disease by selectively inhibiting factor Xa. Clinical trials show reduced thrombosis risk with no increased bleeding, establishing its therapeutic value.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of the effect of oral dienogest and dienogest/ethinylestradiol treatment on cell-free DNA levels in patients with deep endometriosis.

European journal of medical research·2025
Same author

Dynamics of thrombin generation: Filling the gap between the system pharmacology theory and clinical practice in clinical pharmacology and therapeutics.

Pharmacology research & perspectives·2024
Same author

Serological autoimmune profile of systemic lupus erythematosus in deep and non-deep endometriosis patients.

Journal of reproductive immunology·2023
Same author

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same author

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients.

Medicina intensiva·2021
Same author

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients.

Medicina intensiva·2021

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Thromboembolic disease poses significant health risks.
  • Existing anticoagulants have limitations, including potential for heparin-induced thrombocytopenia.
  • Fondaparinux is a synthetic, selective inhibitor of activated factor X, mimicking heparin's antithrombotic action.

Purpose of the Study:

  • To evaluate the efficacy and safety of fondaparinux for the treatment and prophylaxis of thromboembolic disorders.
  • To determine the optimal dosage and administration route for fondaparinux.
  • To compare fondaparinux with existing anticoagulants like enoxaparin and dalteparin.

Main Methods:

  • Phase I, II, and III clinical trials were conducted.
  • Studies involved patients undergoing orthopedic surgery, those with deep venous thrombosis, and patients with acute coronary syndromes.
  • Fondaparinux efficacy and safety were assessed against placebo, enoxaparin, and dalteparin, with outcomes including thrombosis rates, bleeding events, and mortality.

Main Results:

  • Fondaparinux demonstrated 100% bioavailability subcutaneously with a half-life of 13.5 hours.
  • Phase III trials showed a 50% reduction in thrombosis risk in orthopedic surgery patients compared to enoxaparin, with similar bleeding rates.
  • Phase II trials indicated comparable efficacy and bleeding incidence to dalteparin in deep venous thrombosis treatment.

Conclusions:

  • Fondaparinux is an effective anticoagulant for preventing and treating thromboembolic disease.
  • Its selective inhibition of factor Xa offers a favorable safety profile, without affecting coagulation tests or causing heparin-induced thrombocytopenia.
  • Fondaparinux represents a significant advancement in anticoagulant therapy, particularly in orthopedic surgery and deep vein thrombosis management.

Related Experiment Videos